Tiansheng Pharmaceutical Group Co Diluted EPS
Diluted Earnings per Share of Tiansheng Pharmaceutical Group Co (002872.SZ) as of Oct 25, 2026.
Get this data via API
Financial Data API
Diluted EPS
-CNY
Last updated:
Diluted Earnings per Share of Tiansheng Pharmaceutical Group Co is 2026 - CNY. Diluted Earnings per Share of Tiansheng Pharmaceutical Group Co was 2025 - CNY. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Tiansheng Pharmaceutical Group Co Stock analysis
What does Tiansheng Pharmaceutical Group Co do? Tiansheng Pharmaceutical Group Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products primarily within the domestic market. Its main products include pediatric lung cough particles, erythromycin enteric-coated capsules, silver ginseng Tongluo capsules, Salvia granules, Shugan Yi spleen granules, compound Ganoderma lucidum granules, Xiangdan injection, Qi and Diabetes tablets, liver capsule, Ling Jing capsule, lungs of nuclear paste, and Shen Qi Yi lung pill. The company focuses on domestic sales, targeting consumers seeking traditional Chinese medicine solutions for respiratory and digestive health.
The firm's product portfolio emphasizes traditional Chinese medicine formulations, with specific offerings like Shugan Yi spleen granules for digestive issues and Ling Jing capsule for respiratory conditions. These products are distributed through domestic channels, catering to a market segment that prefers herbal remedies over conventional pharmaceuticals. Tiansheng's revenue stream is derived from the sale of these branded pharmaceutical items to pharmacies and healthcare providers within China. Tiansheng Pharmaceutical Group Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Tiansheng Pharmaceutical Group Co stock
On Eulerpool you can find the complete historical development of Diluted Earnings per Share Tiansheng Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.
Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Tiansheng Pharmaceutical Group Co
All Key Metrics — Tiansheng Pharmaceutical Group Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth